Hpk1 Inhibitor CFI-402411

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of the serine/threonine enzyme hematopoietic progenitor kinase-1 (Hpk1; Hpk-1; mitogen-activated protein kinase kinase kinase kinase 1; MAP4K1), with potential immunostimulating and antineoplastic activities. Upon oral administration, Hpk1 inhibitor CFI-402411 targets, binds to and inhibits the activity of Hpk1. This inhibits Hpk1-mediated signaling pathways and inhibits the proliferation of Hpk1-expressing tumor cells. In addition, CFI-402411 prevents Hpk1-mediated immunosuppression by preventing the inhibition of T cell receptors (TCR) signaling and effector T-cells, disrupting abnormal cytokine expression, and abrogating the immunosuppressive tumor microenvironment (TME). This may activate a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Hpk1 is expressed in hematopoietic cells and a negative regulator of TCR and T- and B-cell activation.

**Synonyms:** - CFI 402411 - CFI-402411 - CFI402411 - Hematopoietic Progenitor Kinase 1 Inhibitor CFI-402411 - Hpk-1 Inhibitor CFI-402411